Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049

Document Type : Original Article


1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

2 People’s Hospital Medical Community of Yuhuan County, Taizhou, China


Chronic hepatitis B (CHB) is highly prevalent among adults in rural China and better management of those populations is of vital importance for viral hepatitis elimination. Adult immunization has been the subject of much controversy in previous studies. This study estimates the cost-effectiveness of population-based hepatitis B screening, treatment, and immunization strategy (comprehensive strategy) in rural areas with high prevalence under the national policy of sharp- drop drug prices.
We constructed a Markov model comparing 4 strategies in a 30-year horizon from the healthcare payer perspective: (1) the conventional pattern; (2) screening and treating infected (treatment); (3) screening and immunizing susceptible individuals (immunization); and (4) the comprehensive strategy. Screening intensity ranged from 50% to 100%. Outcomes were measured by costs, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and clinical outcomes.
The costs for the conventional pattern, treatment strategy, immunization strategy, and comprehensive strategy were US$ 341, 351, 318, and 323, respectively. In addition, effects were 17.45, 17.57, 17.46, and 17.58 QALYs, respectively. The ICER of the comprehensive strategy was US$ 35/QALY gained at 50% screening intensity and 420 US$/QALY gained at 100%. The net monetary benefit increased with increasing screening intensity and declined after 90%, with the highest value of US$40 693. All new infections and 52.5% mortality could be avoided from 2020 to 2049 if all patients were properly treated and all susceptible individuals were immunized. The results were stable within a wide range of parameters.
It was cost-effective to implement the mass hepatitis B screening, treatment, and immunization strategy in areas of rural China with high prevalence, and the strategy gained the most net monetary benefit at a screening intensity of 90%. Although it was impractical to fulfill 100% coverage, efforts should be made to obtain more people screened.


  1. World Health Organization (WHO). Global Hepatitis Report 2017. Geneva: WHO; 2017.
  2. Cui F, Shen L, Li L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017;23(5):765-772. doi:3201/eid2305.161477
  3. The Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403. doi:1016/s2468-1253(18)30056-6
  4. Nayagam S, Chan P, Zhao K, et al. Investment case for a comprehensive package of interventions against hepatitis B in China: applied modeling to help national strategy planning. Clin Infect Dis. 2021;72(5):743-752. doi:1093/cid/ciaa134
  5. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. doi:1016/j.jhep.2017.03.021
  6. Nayagam S, Conteh L, Sicuri E, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health. 2016;4(8):e568-578. doi:1016/s2214-109x(16)30101-2
  7. Rossi C, Schwartzman K, Oxlade O, Klein MB, Greenaway C. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. PLoS One. 2013;8(10):e78548. doi:1371/journal.pone.0078548
  8. Zhang GM, Sun XJ, Wang FZ, Zheng H, Gong XH. Analysis of epidemiological characteristics of hepatitis B among the population of 18-59 year old and HepB immunization strategies. Chin J Vaccines Immun. 2013;19(3):266-270.
  9. Pileggi C, Papadopoli R, Bianco A, Pavia M. Hepatitis B vaccine and the need for a booster dose after primary vaccination. Vaccine. 2017;35(46):6302-6307. doi:1016/j.vaccine.2017.09.076
  10. Hoerger TJ, Schillie S, Wittenborn JS, et al. Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes. Diabetes Care. 2013;36(1):63-69. doi:2337/dc12-0759
  11. Mangen MJ, Stibbe H, Urbanus A, et al. Targeted outreach hepatitis B vaccination program in high-risk adults: the fundamental challenge of the last mile. Vaccine. 2017;35(24):3215-3221. doi:1016/j.vaccine.2017.04.068
  12. Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of hepatitis B virus infection screening and treatment or vaccination in 6 high-risk populations in the United States. Open Forum Infect Dis. 2019;6(1):ofy353. doi:1093/ofid/ofy353
  13. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med. 2007;147(7):460-469. doi:7326/0003-4819-147-7-200710020-00004
  14. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550-6557. doi:1016/j.vaccine.2009.08.048
  15. Chinese Medical Association. [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):938-961. doi:3760/cma.j.issn.1007-3418.2019.12.007
  16. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-352. doi:1016/j.jhep.2007.11.011
  17. Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine. 2001;19(15-16):2055-2060. doi:1016/s0264-410x(00)00410-2
  18. Zheng H, Wang FZ, Zhang GM, et al. An economic analysis of adult hepatitis B vaccination in China. Vaccine. 2015;33(48):6831-6839. doi:1016/j.vaccine.2015.09.011
  19. Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46(2):395-401. doi:1002/hep.21724
  20. Lin X, Robinson NJ, Thursz M, et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J Gastroenterol Hepatol. 2005;20(6):833-843. doi:1111/j.1440-1746.2005.03813.x
  21. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261-283. doi:1002/hep.28156
  22. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:1002/hep.29800
  23. Tseng TC, Liu CJ, Chen CL, et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis. 2012;205(1):54-63. doi:1093/infdis/jir687
  24. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol. 2010;53(1):118-125. doi:1016/j.jhep.2010.02.026
  25. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58(5):1537-1547. doi:1002/hep.26301
  26. Jang JW, Choi JY, Kim YS, et al. Effects of virologic response to treatment on short- and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol. 2018;16(12):1954-1963.e1953. doi:1016/j.cgh.2018.04.063
  27. Kanwal F, Hernaez R, Liu Y, et al. Factors associated with access to and receipt of liver transplantation in veterans with end-stage liver disease. JAMA Intern Med. 2021;181(7):949-959. doi:1001/jamainternmed.2021.2051
  28. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57(6):2164-2170. doi:1002/hep.26218
  29. Yang S, Yu C, Chen P, et al. Protective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China. Sci Rep. 2015;5:18334. doi:1038/srep18334
  30. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112-125. doi:1093/epirev/mxj009
  31. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507-539. doi:1002/hep.21513
  32. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11(3):527-538. doi:1111/j.1524-4733.2007.00297.x
  33. Chen P, Yu C, Ruan B, et al. Prevalence of hepatitis B in insular regions of southeast China: a community-based study. PLoS One. 2013;8(2):e56444. doi:1371/journal.pone.0056444
  34. Yu Z, Deng M, Peng C, et al. A system dynamics modelling simulation based on a cohort of hepatitis B epidemic research in east China community. Epidemiol Infect. 2019;147:e86. doi:1017/s0950268819000220
  35. Guilbert JJ. The world health report 2002 - reducing risks, promoting healthy life. Educ Health (Abingdon). 2003;16(2):230. doi:1080/1357628031000116808
  36. Statistical Communique of the People's Republic of China on the 2019 National Economic and Social Development. National Bureau of Statistics website. Accessed June 8, 2021. Updated February 28, 2020.
  37. Jing W, Liu J, Wu Y, Ma Q, Liu M. Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: a decision-analytic Markov model. EClinicalMedicine. 2020;19:100264. doi:1016/j.eclinm.2020.100264
  38. Tatar M, Keeshin SW, Mailliard M, Wilson FA. Cost-effectiveness of universal and targeted hepatitis C virus screening in the United States. JAMA Netw Open. 2020;3(9):e2015756. doi:1001/jamanetworkopen.2020.15756
  39. Hou JL, Wei L, Wang GQ, Jia JD, Duan ZP, Zhuang H. [Clinical cure of hepatitis B: consensus and controversy]. Zhonghua Gan Zang Bing Za Zhi. 2020;28(8):636-639. doi:3760/cma.j.cn501113-20200722-00409
Volume 11, Issue 10
October 2022
Pages 2115-2123
  • Receive Date: 29 March 2021
  • Revise Date: 09 August 2021
  • Accept Date: 04 September 2021
  • First Publish Date: 07 September 2021